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Mutations in SPATA5 Are Associated with Microcephaly,
Intellectual Disability, Seizures, and Hearing Loss
Akemi J. Tanaka,1 Megan T. Cho,2 Francisca Millan,2 Jane Juusola,2 Kyle Retterer,2 Charuta Joshi,3
Dmitriy Niyazov,4 Adolfo Garnica,5 Edward Gratz,6 Matthew Deardorff,7 Alisha Wilkins,7
Xilma Ortiz-Gonzalez,8 Katherine Mathews,3 Karin Panzer,9 Eva Brilstra,10 Koen L.I. van Gassen,10
Catharina M.L. Volker-Touw,10 Ellen van Binsbergen,10 Nara Sobreira,11 Ada Hamosh,11
Dianalee McKnight,2 Kristin G. Monaghan,2 and Wendy K. Chung1,12,*
Using whole-exome sequencing, we have identified in ten families 14 individuals with microcephaly, developmental delay, intellectual
disability, hypotonia, spasticity, seizures, sensorineural hearing loss, cortical visual impairment, and rare autosomal-recessive predicted
pathogenic variants in spermatogenesis-associated protein 5 (SPATA5). SPATA5 encodes a ubiquitously expressed member of the ATPase
associated with diverse activities (AAA) protein family and is involved in mitochondrial morphogenesis during early spermatogenesis. It
might also play a role in post-translational modification during cell differentiation in neuronal development. Mutations in SPATA5
might affect brain development and function, resulting in microcephaly, developmental delay, and intellectual disability.Whole-exome sequencing (WES) is an emerging clinical
tool for identifying genes associated with genetically
heterogeneous disorders, such as global developmental
delay,1 intellectual disability (ID),2 schizophrenia,3 and
epilepsy.4 In individuals in whom initial diagnostic
workup and genetic evaluation are unrevealing and
without specific clinical features to suggest a diagnosis,
WES with the inclusion of parents can be a powerful tool
for identifying de novo and inherited rare variants.1,5
Here, we describe 14 individuals who are from ten inde-
pendent families and who have homozygous or com-
pound-heterozygous rare variants that are predicted to
be deleterious. SPATA5 (MIM: 613940; GenBank: NM_
145207.2) is located in chromosomal region 4q28.1 and
encodes a member of the ATPase associated with diverse
activities (AAA) protein family. Common features in these
individuals include microcephaly, ID, generalized intrac-
table epilepsy, hypotonia, spasticity, sensorineural hearing
loss, and cortical visual defects.
Clinical WES was performed on 3,359 individuals with
developmental delay, ID, or seizures in one clinical labora-
tory. In ten affected children from seven unrelated fam-
ilies, we identified variants in SPATA5 as potentially
causative for the phenotype. Through GeneMatcher,6
we identified four additional probands from three families,
giving us a total of 14 affected children in ten families.
Twelve of the individuals are of European descent,
and two (individuals 6 and 7) are Hispanic. All of the
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The Americanproband-parent trio analysis or a family analysis using
affected or unaffected siblings in the segregation analysis
(Figure S2). Informed consent was obtained for each
individual.
Genomic DNAwas extracted from whole blood from the
affected children and their parents. Exome sequencing at
GeneDx was performed on exon targets isolated by capture
with the Agilent SureSelect Human All Exon V4 (50 Mb)
Kit (Agilent Technologies). One microgram of DNA from
blood specimen was sheared into 350- to 400-bp frag-
ments, which were then repaired, ligated to adaptors,
and purified for subsequent PCR amplification. Amplified
products were then captured by biotinylated RNA library
baits in solution according to the manufacturer’s instruc-
tions. Bound DNA was isolated with streptavidin-coated
beads and re-amplified. The final isolated products were
sequenced with the Illumina HiSeq 2000 or 2500
sequencing system with 100-bp paired-end reads. At the
time of sequencing, DNA sequence was mapped to the
reference human genome sequence (UCSC Genome
Browser hg19) with the latest internally validated version
of the Burrows-Wheeler Aligner (BWA), progressing from
BWA v.0.5.8 to BWA-Mem v.0.7.8.7,8 Targeted coding
exons and splice junctions of known protein-coding Re-
fSeq genes were assessed for average depth of coverage,
and a minimum depth of 103 was required for inclusion
in downstream analysis. Local realignment around
insertion-deletion sites was performed with the Genome
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simultaneously on all sequenced family members with
SAMtools v.0.1.18.10 All coding exons and surround-
ing intron-exon boundaries were analyzed. Automated
filtering removed common sequence changes (defined
as >10% frequency present in 1000 Genomes). The tar-
geted coding exons and splice junctions of the known
protein-coding RefSeq genes were assessed for the average
depth of coverage and data-quality threshold values.
WES data for all sequenced family members were analyzed
with GeneDx’s XomeAnalyzer (a variant annotation,
filtering, and viewing interface for WES data), which in-
cludes nucleotide and amino acid annotations, population
frequencies (from the NHLBI Exome Sequencing Project
Exome Variant Server and 1000 Genomes), in silico predic-
tion tools, amino acid conservation scores, and mutation
references. Variants were filtered on the basis of inheri-
tance patterns, lists of genes of interest, and phenotype
and population frequencies, as appropriate. Resources
including the Human Gene Mutation Database, 1000 Ge-
nomes, the NHLBI Exome Variant Server, OMIM, PubMed,
and ClinVar were used for evaluating genes and detecting
sequence changes of interest. Additional searches were per-
formed with specific lists of genes related to ID. Identified
sequence changes of interest were confirmed in all mem-
bers of the trio by conventional di-deoxy DNA sequence
analysis on an ABI3730 (Life Technologies) according to
standard protocols with an additional DNA preparation.
To design the prioritization strategy, we used the
PhenoDB Variant Analysis Tool6 to analyze the exomes
sequenced at the Baylor-Hopkins Center forMendelian Ge-
nomics. We prioritized rare functional variants (missense
variants, nonsense variants, splice-site variants, and indels)
that were homozygous, compound heterozygous, or in
the proband but not in the unaffected sibling and excluded
variants with a minor allele frequency > 0.01 in dbSNP
builds 126, 129, and 131, the Exome Variant Server (release
ESP6500SI-V2), or 1000 Genomes. We also excluded all
variants found in our in-house control individuals
(CIDRVar 51Mb).With that, we generated lists of homozy-
gous and compound-heterozygous variants for the affected
siblings.
The exomes sequenced in the Netherlands were en-
riched with the SureSelect XT Human All Exon V5 Kit (Agi-
lent) and sequenced in rapid mode on the HiSeq 2500
sequencing system (Illumina) at a mean target depth of
1003 (target defined as coding exons in the UCSC
Genome Browser and Ensembl 5 20-bp intron flanks). At
this depth, >95% of the target was covered at >103.
Detected variants were annotated and filtered with the
Bench Lab NGS platform (Cartagenia). Probably delete-
rious SPATA5 variants consistent with autosomal-recessive
inheritance were identified in both individuals. After
matches were identified in the GeneMatcher database,
these variants were reported as potentially causative
mutations.
Exome sequencing from seven affected childrens’
samples analyzed at the original clinical laboratory pro-458 The American Journal of Human Genetics 97, 457–464, Septembduced an average of ~11 Gb of sequence per sample.
Mean coverage of the captured regions was ~1403 per sam-
ple, >98% was covered at >103 coverage, an average
of >92% of base call quality scores were RQ30, and the
overall mean quality score was>Q36.Whenwe considered
all possible modes of inheritance, filtering of common
SNPs (>10% frequency in 1000 Genomes) resulted in
~5,400 variants per proband sample in 548 genes (974
unique sequence changes) of interest identified across
seven families (Table S1). We evaluated each of these 548
genes by variant allele frequency in reference populations,
known disease association, pattern of inheritance, and
similarity of clinical phenotype, leaving one gene of
interest: SPATA5 (Table S1). Variants were confirmed by
Sanger sequencing. All 15 variants identified in the ten
families are rare and highly conserved throughout
evolution. Eight of the variants are predicted to be
deleterious by PolyPhen-2, SIFT, CADD, MetaSVM, and
MutationTaster (Table 1). The c.251G>A (p.Arg84Gln),
c.1343C>T (p.Ser448Leu), c.989_991del (p.Thr330del),
c.1883A>G (p.Asp628Gly), and splice c.1714þ1G>A vari-
ants were each detected in the Exome Aggregation Con-
sortium (ExAC) Browser with an allele frequency
of <1/10,000 (Table 1). No other variants are present in
the ExAC Browser, 1000 Genomes, Exome Variant Server,
or dbSNP. No homozygous loss-of-function variants were
detected in the ExAC Browser, 1000 Genomes, Exome
Variant Server, or our own internal database of 15,716
exomes. Only one person had a homozygous variant,
and all other individuals had compound-heterozygous
variants. There were ninemissensemutations, three frame-
shift mutations, one in-frame deletion, one nonsense
mutation, and one splice-site mutation. The c.556C>T
(p.Arg186*) and c.251G>A (p.Arg84Gln) mutations were
each identified independently in two unrelated families.
The c.556C>T mutation was part of a shared haplo-
type. In all families, parents were heterozygous, and
the unaffected siblings of individual 5 were each heterozy-
gous for either the c.298G>A (p.Ala100Thr) or the
c.556C>T (p.Arg186*) variant, supporting autosomal-
recessive inheritance.
Fourteen individuals from ten independent families
share similar clinical features, including microcephaly,
neurodevelopmental delay, seizures, and sensorineural
hearing loss (Tables 2 and S2). The children range in age
from 2 to 19 years, and all have moderate to severe ID.
All 14 individuals had abnormal electroencephalograms
with generalized intractable epilepsy, including tonic
clonic, myoclonic, and absence seizures, as well as staring
spells. Twelve of the 14 individuals have hypotonia, three
have hypertonia, and seven have spasticity. Vision is vari-
ably impaired in 14 children and includes cortical visual
impairment in seven. Hearing is impaired in all 14 of the
children, nine of whom have congenital bilateral sensori-
neural hearing loss and three of whom have acquired bilat-
eral sensorineural hearing loss. Notably, speech did not
improve in one child whose hearing was corrected.er 3, 2015
Table 1. Predicted Pathogenicity and Allele Frequencies of SPATA5 Variants
Amino Acid
Change
Chromosome 4
Coordinates Nucleotide Change SIFT PROVEAN PolyPhen-2 MutationTaster MetaSVM
CADD
Phred
Allele Frequency
ExAC
1000
Genomes EVS XomeDx
p.Arg84Gln 123848876G>A c.251G>A tolerated
(0.111)
neutral
(0.653)
possibly
damaging
(0.849)
disease causing
(0.39392)
deleterious
(0.88398)
22.30 0.00004118 0 0 0.0003
p.Ser90Ile 123848894G>T c.269G>T damaging
(0.001)
neutral
(2.020)
possibly
damaging
(0.873)
disease causing
(0.34117)
deleterious
(0.86851)
17.76 0 0 0 0.0001
p.Ala100Thr 123850204G>A c.298G>A damaging
(0.002)
neutral
(2.020)
damaging
(0.960)
disease causing
(0.997)
deleterious
(0.90678)
27.60 0 0 0 0.0001
p.Arg186* 123855302C>T c.556C>T NA NA NA disease causing
(0.70825)
NA 37.00 0 0 0 0.0001
p.Thr330del 123855735_
123855737del
c.989_991del NA deleterious
(4.557)
damaging disease causing unknown 22.40 0.0001334 0 0 0
p.Ser448Leu 123859289C>T c.1343C>T damaging
(0.001)
deleterious
(4.648)
possibly
damaging
(0.672)
disease causing
(0.35151)
deleterious
(0.97264)
24.40 0.00002471 0 0 0.0001
p.Asn525Thrfs*20 123868503_
123868507del
c.1574_1578delATGCT NA NA NA NA NA NA 0 0 0 0.0001
p.Arg529Gln 123868515G>A c.1586G>A damaging
(0.000)
deleterious
(3.731)
damaging
(0.985)
disease causing
(0.70825)
deleterious
(0.99505)
34.00 0.00002471 0 0 0.0001
p.Tyr559* 123868606C>A c.1677C>A NA NA damaging disease causing unknown 37.00 0 0 0 0
NA 123868644G>A c.1714þ1G>A NA NA unknown disease causing
(1.000)
unknown 16.40 0.0001341 0 0.00015378 0
p.Trp626Cys 123949349G>C c.1878G>C damaging
(0.000)
deleterious
(12.091)
damaging
(0.946)
disease causing
(0.40733)
deleterious
(0.99215)
21.90 0 0 0 0
p.Asp628Gly 123949354A>G c.1883A>G damaging
(0.001)
deleterious
(6.762)
damaging
(0.97)
disease causing
(0.70825)
deleterious
(0.99139)
32.00 0.00003295 0 0 0.0001
p.Arg784Gln 124177181G>A c.2351G>A damaging
(0.001)
deleterious
(3.835)
damaging
(0.971)
disease causing
(0.40733)
deleterious
(0.99177)
21.80 0 0 0 0.0001
p.Ile788Serfs*47 124177192_
124177201del
c.2362_
2371delATTGATAGAA
NA NA NA NA NA NA 0 0 0 0.0001
p.Ala844Val 124235068C>T c.2531C>T tolerated
(0.085)
deleterious
(3.512)
possibly
damaging
(0.723)
disease causing
(0.3652)
deleterious
(0.95928)
24.80 0 0 0 0.0001
The following abbreviation is used: NA, not applicable.
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Table 2. Clinical Features of Individuals with Mutations in SPATA5
Individual
Age
(Years) Sex
Proband
or Sibling Nucleotide and Amino Acid Changes Hypotonia Spasticity DD
Vision
Defect SNHL Microcephaly Brain MRI Seizure
Abnormal
EEG GI
1 6 F P c.2531C>T (p.Ala844Val),
c.1574_1578delATGCT (p.Asn525Thrfs*20)
þ þ þ þ þ þ thin corpus callosum  þ þ
2 9 F S of 1 c.2531C>T (p.Ala844Val),
c.1574_1578delATGCT (p.Asn525Thrfs*20)
þ þ þ þ þ þ thin corpus callosum þ þ þ
3 5 F P c.2362_2371delATTGATAGAA
(p.Ile788Serfs*47), c.251G>A (p.Arg84Gln)
þ þ þ þ þ þ delayed myelination þ þ þ
4 4 F P c.1343C>T (p.Ser448Leu), c.556C>T
(p.Arg186*)
þ  þ þ þ þ normal þ þ þ
5 2 F P c.298G>A (p.Ala100Thr), c.556C>T
(p.Arg186*)
þ þ þ þ þ þ hypomyelination þ þ þ
6 11 M P c.2351G>A (p.Arg784Gln), c.269G>T
(p.Ser90Ile)
þ þ þ þ þ þ progressive diffuse
atrophy
þ þ þ
7 6 F S of 6 c.2351G>A (p.Arg784Gln), c.269G>T
(p.Ser90Ile)
þ  þ ND þ þ normal þ þ þ
8 19 M P c.1883A>G (p.Asp628Gly), c.1586G>A
(p.Arg529Gln)
þ þ þ þ þ ND cortical atrophy,
immature myelination
þ þ þ
9 14 F S of 8 c.1883A>G (p.Asp628Gly), c.1586G>A
(p.Arg529Gln)
þ  þ þ þ þ ND þ þ 
10 8 M P c.1878G>C (p.Trp626Cys), c.1714þ1G>A hypertonia þ þ þ þ þ normal þ þ þ
11 3 M S of 10 c.1878G>C (p.Trp626Cys), c.1714þ1G>A þ  þ þ þ þ ND þ þ þ
12 5 M P c.1883A>G (p.Asp628Gly), c.1677C>A
(p.Tyr559*)
þ þ þ þ þ  enlarged cerebrospinal
fluid spaces
þ þ þ
13 11 F P c.989_991del (p.Thr330del) þ  þ þ þ þ normal þ þ þ
14 4 M P c.251G>A (p.Arg84Gln) þ þ þ þ þ þ normal þ þ þ
See Table S2 for additional details of clinical presentations. Abbreviations are as follows: DD, developmental delay; EEG, electroencephalogram; GI, gastrointestinal issues; ND, not determined because of availability or appli-
cability; P, proband; S, sibling; SNHL, sensorineural hearing loss.
4
6
0
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
7
,
4
5
7
–
4
6
4
,
S
e
p
te
m
b
e
r
3
,
2
0
1
5
Microcephaly was observed in at least 12 individuals, four
of whom have congenital microcephaly and another four
of whom have acquired microcephaly. A single 5-year-old
child has a history of developmental regression. Brain
MRI was performed and demonstrated abnormalities in
seven of the individuals as diffuse atrophy, cortical
atrophy, thin corpus callosum, and hypomyelination
(Figure S1). Four of the individuals have scoliosis, and
four children also have hip dysplasia or hip dislocations.
Two individuals have short stature, six have shown failure
to thrive, and six require feeding by a gastrostomy tube.
Gastrointestinal issues include gastrointestinal reflux
disease in four of the children and constipation in
three. Thrombocytopenia was observed in three of the
individuals, and four are also immunodeficient. Individual
2 is being monitored by an immunologist for dysgamma-
globulinemia and is being treated with intravenous
immunoglobulin. Generally, the individuals do not have
dysmorphic features.
For individuals 3 and 14, muscle biopsies revealed a
possible mitochondrial disorder. Electron microscopy
demonstrated enlarged and abnormally shaped mitochon-
dria in individual 3. Individual 14’s muscle biopsy showed
intermyofibrillar linear mitochondrial aggregates, a mild
increase in subsarcolemmal and intermyofibrillar mito-
chondria, and reduced electron transport chain activity,
possibly indicating mitochondrial dysfunction.
We describe a clinical syndrome characterized by severe
neurological impairment including ID, generalized intrac-
table epilepsy, microcephaly, abnormal muscle tone, and
sensorineural hearing loss due to autosomal-recessive
pathogenic variants in SPATA5. Although they were not
observed in every person, cortical visual impairment, prob-
lems with feeding and growth, spasticity, scoliosis, immu-
nodeficiency, and thrombocytopenia were also common
features (Table S2).
All of our individuals have mutations in SPATA5 regions
that are highly conserved throughout evolution (Figure 1).
A total of 15 independent variants were identified byWES.
Individual 13 is homozygous for the c.989_991del
(p.Thr330del) in-frame deletion variant, which is a dele-
tion of the highly evolutionarily conserved threonine
330 and was previously reported by Xu and colleagues3
as a de novo pathogenic variant in a schizophrenia child-
parent trio. Notably, there is no known family history of
mental illness in the parents of our individual, suggesting
that this variant alone might not be the cause of the
schizophrenia in the subject reported by Xu et al.3 Nine
of the variants are nonsynonymous missense substitutions
and occur in highly conserved regions of SPATA5; two
occur in AAA domains, and three occur in the CDC48
N-terminal domain, an evolutionarily conserved substrate
recognition domain that binds to polypeptides, prevents
protein aggregation, and is involved in protein folding.
The recurrent p.Arg186* variant in individuals 4 and 5
is part of a common haplotype, and the arginine 186 resi-
due is located within a putative ubiquitylation site inThe AmericanSPATA5.The two frameshift variants affecting the AAA do-
mains—p.Arg186* and splice-site variant c.1714þ1G>A—
are predicted to disrupt or cause loss of protein function
through either nonsense-mediated mRNA decay or protein
truncation.
SPATA5 is located in chromosomal region 4q28.1 and en-
codes a member of the AAA protein family. AAA family
members are defined by a highly conserved ATPase
domain, which is involved in a variety of cellular pro-
cesses, including protein unfolding and degradation,
microtubule motor movement, DNA replication, and
membrane fusion. Pathogenic variants in AAA proteins
lead to various disorders, including hereditary spastic
paraplegia (MIM: 607259), Zellweger syndrome (MIM:
214100), early-onset torsion dystonia (MIM: 605204),
and Paget disease with frontotemporal dementia (MIM:
601023). Hereditary spastic paraplegia results from auto-
somal-dominant gene-disrupting mutations affecting the
AAA domain of spastin, a microtubule regulator, or
from a variety of autosomal-recessive mutations, includ-
ing frameshift insertion-deletions, splice-site mutations,
missense mutations, and nonsense mutations in the para-
plegin gene, which encodes a mitochondrial protease. Zell-
weger syndrome is caused by mutations in genes encoding
peroxisomal matrix proteins. The most common sequence
change is p.Gly843Asp (c.2528G>A) in PEX1, which is
responsible for over a third of cases. Early-onset torsion
dystonia is the result of a single amino acid deletion in
torsinA, an endoplasmic reticulum lumen protein. Paget
disease with frontotemporal dementia results from
missense variants in p97, an abundant AAA protein
involved in cellular activities such as ERmembrane protein
degradation and ubiquitin homeostasis.14,15
SPATA5 is an 892-amino-acid protein first identified in
mouse testes as a spermatogenesis associated factor
(SPAF) that might be involved in regulating the structural
integrity of mitochondria during spermatogenesis.16
SPATA5 consists of a putative mitochondrial targeting
sequence and two AAA domains and is expressed ubiqui-
tously, including in the testes, spleen, skin, intestines,
and brain. Paraplegin, an AAA protein similar to SPATA5,
is an ATP-dependent component of a mitochondrial prote-
ase complex and is altered in individuals with complex
hereditary spastic paraplegia.17 Paraplegin is required for
ribosome assembly and translation in mitochondria.
Loss-of-function autosomal-recessive pathogenic variants
in paraplegin result in a complex I deficiency and increased
sensitivity to oxidative stress.18,19 Another AAA family
member, Lon, is a proteolytic ATPase that influences mito-
chondrial and respiratory function. Homozygous and
compound-heterozygous mutations in LONP1 cause cere-
bral, ocular, dental, auricular, skeletal (CODAS) syndrome,
characterized by developmental delay, hearing loss, skel-
etal defects, and craniofacial anomalies.20 Although the
specific function of SPATA5 is unknown, one possible
role for SPATA5 is in mitochondrial integrity and func-
tion and would explain the predominant neurologicalJournal of Human Genetics 97, 457–464, September 3, 2015 461
Figure 1. Variants in SPATA5
(A) Diagram of SPATA5 with variants identified in green. Missense and in-frame deletions are shown below, and gene-disrupting variants
are shown above.
(B) Sequence alignment of the CDC48N-terminal domain (turquoise), AAAdomains (yellow), andWalker A,Walker B, and second region
ofhomology (SRH)motifs (blue text, underlined). Aputativemitochondria-targeting sequence is highlighted ingreen, andpotential ubiq-
uitination sites11–13 are in gray. Residues altered in (A) are shown in bold red text. Species abbreviations are as follows: chimpanzee (Pantr,
Pan troglodytes), fruit fly (Drome, Drosophila melanogaster), nematode (Cael, C. elegans), and budding yeast (Yeast, S. cerevisiae).
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phenotype. It has been suggested that SPATA5 is involved
in the morphological transformation of mitochondria
from an ‘‘orthodox’’ to a ‘‘condensed’’ form, which occurs
during differentiation in spermatogenesis and might be a
mechanism to compensate for the thermodynamically un-
favorable conditions and decreased oxygen supply due to
the blood-testis barrier for differentiating cells in the adlu-
minal compartment. Mitochondrial morphogenesis plays
an important role in synaptic development and plasticity,
and disruptions in this process are associated with neuro-
degenerative disorders.21,22 The abnormally shaped mito-
chondria in individuals 3 and 14 might be due to defects
in SPATA5 function.
Functional assays in yeast have shown that the yeast ho-
molog Afg2 (ATPase family gene) is essential for the release
and recycling of nucleolar shuttling factors from pre-60S ri-
bosomal particles.23,24 AAA proteins act as chaperones that
bind and change the conformation of substrates during
their ATPase cycle. Upon binding ATP and hydrolysis,
the force generated by an AAA protein is propagated to
its bound substrates and thus allows the ATP-dependent
structural or conformational change of the substrate, re-
sulting in translocation or remodeling and unfolding or
disassembly of protein complexes.15 Heallen and col-
leagues25 showed that theC. elegans gene cdc-48.3 is closely
related to yeast AFG2 and mammalian SPATA5 and regu-
lates the stability, activity, and localization of aurora B
kinase AIR-2 during embryonic development. Aurora B ki-
nase is a highly conserved member of the aurora kinase
family of serine threonine kinases and is a key regulator
of mitosis. The authors reported that depletion of CDC-
48.3 leads to mitotic delays and spindle defects and re-
vealed through site-directed mutagenesis studies that
negative regulation of AIR-2 activity occurs by binding of
the CDC-48.3 N terminus to AIR-2 and is also dependent
on the ATPase activity of CDC-48.3. Proteins involved in
the proper alignment of the mitotic spindle are important
for maintaining symmetric and asymmetric cell divisions
and for controlling cell proliferation. Spindle orientation
defects have been associated with neurological and brain
diseases, including lissencephaly and primary micro-
cephaly,26 and therefore could also account for the
congenital microcephaly observed in individuals with
SPATA5 mutations.
SPATA5 is developmentally expressed throughout the
brain, including in the cerebral cortex and hippocam-
pus,27,28 andmight play a critical role in neuronal develop-
ment and growth. Disrupted mitochondrial morphogen-
esis during development might lead to neurological
disorders, including cognitive impairment, behavioral
deficits, and motor sensory dysfunction, as a result of de-
fects in specific neural circuitry. Functional studies of
SPATA5 are necessary for determining its role in various
cellular processes, especially in the brain, and further
investigation of individuals with SPATA5 mutations is
essential for elucidating the correlation between genotype
and phenotype.The AmericanAccession Numbers
Theaccessionnumbers for theDNA-variant data reported in thispa-
per are ClinVar: SCV000238563, SCV000238564, SCV000238567,
SCV000238568, SCV000238569, SCV000238570, SCV000238571,
SCV000238572, SCV000238574, SCV000238576, and
SCV000239917, SCV000240179, SCV000240180, SCV000240214,
SCV000240215.Supplemental Data
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